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ABSTRACT
Conventional two-dimensional (2D) treatment planning of intracavitary brachytherapy is still a common practice at 
the radiotherapy center. The purpose of this study was to evaluate the organ at risk (OAR) doses estimated based on 
International Commission on Radiation Units and Measurements (ICRU) reference-point in patients with cervical cancer 
treated with high-dose-rate (HDR) intracavitary brachytherapy (ICBT). Between January 2010 and April 2014, 21 cervical 
cancer patients were treated with 42 fractions of brachytherapy using tandem and ovoids and underwent post-implant 
two-dimensional (2D) radiograph scans. HDR brachytherapy was delivered to a dose of 18 Gy in two fractions. Using 
the Oncentra brachytherapy treatment planning system (BTPS) software version 4.1 (Nucletron, Netherlands), the bladder 
and rectum points were retrospectively reconstructed based on 42 orthogonal radiographs datasets. The ICRU bladder 
and rectum point doses were recorded. As for results, the mean percentage dose of rectum and bladder for selected 
patients treated with intracavitary brachytherapy treatment (ICBT) were 47.27 and 75.59%, respectively. Combinations 
of ovoid’s size, length of tandem and anatomy variation between each patient were factors that affected the dose to the 
OAR. Therefore, the ICRU reference points can still be used with the 2D brachytherapy treatment planning in evaluating 
the OAR doses. 
Keywords: International Commission on Radiation Units and Measurements (ICRU) reference points; intracavitary 
brachytherapy treatment (ICBT); organ at risk (OAR) doses; two-dimensional (2D) treatment planning
ABSTRAK
Perancangan konvensional dua dimensi (2D) rawatan brakiterapi intrarongga masih merupakan amalan biasa di 
sesetengah pusat radioterapi. Tujuan kajian retrospektif ini dijalankan adalah untuk menilai dos pada organ berisiko 
(OAR) berdasarkan syor oleh Suruhanjaya Antarabangsa mengenai Unit Sinaran dan Pengukuran (ICRU) pada pesakit 
dengan kanser serviks dirawat dengan dos berkadar tinggi (HDR) brakiterapi intrarongga (ICBT). Antara Januari 2010 
dan April 2014, 21 pesakit kanser serviks telah dirawat dengan 42 pecahan brakiterapi menggunakan tandem dan ovoid 
serta menjalani imbasan dua dimensi (2D) radiografi pasca-implan. Dos rawatan HDR brakiterapi yang digunakan 
adalah sebanyak 18 Gy dalam dua fraksi. Menggunakan perancangan rawatan brakiterapi Oncentra perisian 4.1 
(Nucletron, Netherlands), titik pundi kencing dan rektum telah ditandakan semula pada 42 radiografi ortogonal dalam 
kajian retrospektif ini. Hasil kajian menunjukkan peratusan dos purata rektum dan pundi kencing bagi pesakit dipilih 
dirawat dengan ICBT masing-masing 47.27 dan 75.59%. Kombinasi saiz ovoid, panjang tandem dan anatomi yang 
berbeza antara pesakit merupakan beberapa faktor yang memberi kesan dos terhadap OAR. Oleh itu, titik rujukan ICRU 
dalam 2D perancangan rawatan brakiterapi masih boleh digunakan untuk menganggar dos OAR. 
Kata kunci: Dos pada organ berisiko (OAR); mata rujukan Suruhanjaya Antarabangsa mengenai Unit Sinaran dan 
Pengukuran (ICRU); perancangan rawatan dua dimensi (2D); rawatan brakiterapi intrarongga (ICBT)
INTRODUCTION
According to the National Cancer Registry Report (2002), 
cervix uteri cancer is the second most common form of 
cancer that strikes Malaysian women. Furthermore, it is 
the fourth most common cause of death among Malaysian 
women. It is uncommon before the age of 30 years old; 
the risk of developing it increases with age, with a peak 
incidence at ages 60 to 69 years old and declining thereafter. 
In 2006, there were 19 radiotherapy and oncology centers 
in this country comprising 5 public hospitals and 14 private 
centers (Lim 2006). These centers provided radiotherapy 
treatment facilities that consist of 25 linear accelerators, 
7 cobalt-60 teletherapy machines, 15 brachytherapy units, 
11 simulators and 4 computed tomography (CT) simulation 
units to the whole nation. 
 Brachytherapy treatment is delivered after cervical 
cancer patient completed external beam radiotherapy 
treatment (EBRT) to enhance the dose to the tumour 
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while sparing the surrounding healthy tissue. In some 
cancer center that do not have computed tomography 
(CT) simulator, orthogonal radiographs are taken using 
conventional simulator and planned with two-dimensional 
(2D) treatment planning, which is a common practice for 
intracavitary brachytherapy treatment. For ICBT, the dose 
was prescribed to point A. Point A as recommended by 
Manchester system was originally defined as 2 cm superior 
to the lateral vaginal fornix and 2 cm lateral to the cervical 
canal (Khan 2010). The duration of the treatment is based 
on the dose rate calculated at point A, although the dose 
at the other points is taken into consideration in evaluating 
a treatment plan. With the availability of the treatment-
planning computers, most users of the Manchester system 
examine the isodose distributions in the frontal and sagittal 
planes in addition to obtaining dose at point A and at the 
same time dose to OAR such as bladder and rectum. 
 Meanwhile, the most frequent clinical complications of 
the treatments result from a high dose delivered to portions 
of the rectum and bladder that are in close proximity to 
the irradiation area. Applicator placement in intracavitary 
brachytherapy is very important in order to keep the 
dose received by these critical organs as low as possible. 
Therefore the dose received by these two organs must be 
evaluated in order to avoid complications. Bladder and 
rectum point doses can be estimated using recommendation 
by ICRU report No. 38 (1985) reference points for 2D 
planning. The simplicity and cost-effectiveness of 
radiograph-based 2D planning has ensured its continued 
applicability for dose reporting in brachytherapy (Patil et 
al. 2011). Thus, the purpose of this study was to evaluate 
organ at risk (OAR) doses estimated based on International 
Commission on Radiation Units and Measurements (ICRU) 
reference-point in patients with cervical cancer treated with 
high –dose-rate (HDR) intracavitary brachytherapy (ICBT).
MATERIALS AND METHODS
This is a retrospective study of 21 cervical cancer patients 
who underwent radical radiotherapy treatment in Hospital 
Universiti Sains Malaysia (Hospital USM). Twenty one 
cancer patients (age, 41-71 years old) with the International 
Federation of Gyncology and Obstetricts (FIGO) stage of IIB 
to IVA treated between January 2010 and April 2014 were 
selected in this study. All patients underwent external beam 
radiotherapy followed by. All selected patients were treated 
with a standard treatment for cervical cancer consists of 
external beam radiotherapy (EBRT) and followed with 
digital orthogonal radiographs based HDR intracavitary 
brachytherapy. Either anterior-posterior (AP) parallel 
opposed or four-field box beams (depend on the patient’s 
body separation) was used for EBRT in treating cervical 
area. 45 Gy were prescribed to the midplane of the patient’s 
body and delivered in 20 to 25 fractions of EBRT in 4 or 5 
weeks. After the EBRT treatment, these patients underwent 
2 fractions of HDR brachytherapy treatment once a week. 9 
Gy was prescribed for each fraction of the treatment. The 
dose was prescribed at point A as recommended by the 
Manchester system. Two types of applicator combinations 
commonly used for intracavitary brachytherapy are 
Fletcher-Williamson applicator set (consist of a tandem 
and a pair of ovoid) and a ring applicator set (consist of 
a ring and a tandem applicators) as illustrated in Figures 
1 and 2. Fletcher-suit type of applicators (Nucletron, 
Netherlands) is a pair of ovoids and the diameters of 
15, 20 and 25 mm are commonly used. Meanwhile, 
Williamson type of applicator (Nucletron, Netherlands) is 
a tandem applicator with 3 different angles of 15, 30 and 
45°. For the ring applicator set, 2 diameter sizes that are 
commonly used which are 2.6 and 3.2 cm and combined 
with 45° angle of a tandem applicator. The Ir-192 source 
was used as a radiation source for high-dose-rate (HDR) 
brachytherapy microSelectron remote afterloader treatment 
unit (Nucletron, Netherlands). 
INTRACAVITARY BRACHYTHERAPY
Each application was performed under spinal anaesthesia 
in the lithotomy position. Foley balloon was inserted to 
the patient’s body and filled with 7 cc of potassium iodide 
(KI) diluted in normal saline. Then, it was pulled down 
to be seated on the bladder trigone. Rectal probe is also 
inserted to the patient’s body and placed in the rectum. 
The selections of the applicator set applied to patient were 
chosen according to the suitability of patient’s anatomical 
structures. Packing procedure was conducted during 
insertion of applicators to avoid any shifts or changes in 
the geometry of the applicators position and at the same 
time prevent the relocation of rectum and bladder. The 
OAR markers and applicators were checked to position 
the probe at the right place before patients moved to the 
simulation room.
 For simulation procedures, x-ray markers or dummies 
were inserted through the applicator’s cavity. The markers 
are function to visualize the image of each applicator 
on the radiographs and source loading positions in 
treatment planning. Anterior-posterior (AP) and lateral 
view (orthogonal radiographs) of the patients were taken 
using Simulix digital simulator (Nucletron, Netherlands). 
The radiographs taken should clearly visualize the 
bonny structures of pelvic region, dummies inside each 
applicator and OAR markers. The radiographs were stored 
in the simulator workstation. In this study, orthogonal 
radiographs of selected patients were exported to the 
treatment planning system workstation in digital imaging 
and communications in medicine (DICOM) files through 
local area network (LAN).
 Based on the radiograph images of dummy inside each 
applicators, the source positions, OAR reference points and 
each applicators were then retrospectively reconstructed 
using Oncentra Brachytherapy Treatment Planning System 
(BTPS) Software Version 4.1 (Nucletron, Netherlands). 
Sources positions through the applicator were planned 
accordingly to cover the targeted area. 9 Gy was prescribed 
to point A and then the calculation algorithm calculated the 
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dose (Figure 3). The ICRU bladder and rectum point doses 
were recorded. The mean percentage of OAR doses were 
calculated using the following formula:
As example for mean percentage of bladder dose (Rb) for 
both fractions of ICBT, where f1 was first fraction and f2 
was second fraction.
  (1)
 The same formula was applied for calculating the 
mean percentage dose for rectum. As a standard department 
practice, the dose to bladder and rectum should not exceed 
80 and 60% of dose to point A, respectively, in order to 
keep the dose to the both organs less than their tolerance 
dose (less than 60 Gy for bladder and less than 50 Gy for 
rectum) (Figure 4).
 RESULTS AND DISCUSSION
Figure 5 shows the comparison of bladder doses for each 
fraction of ICBT for 21 selected patients. 52.4% exceeded 
80% of dose to point A for the first fraction (11 out of 21 
plans) and reduced to 27.6% (6 out of 21 plans) for the 
second fraction. Figure 6 shows the comparison of rectum 
doses for each fraction of ICBT for 21 selected patients. 
19.0% (4 out of 21 plans) exceeded 60% of dose to point 
A for the first fraction and reduced to 14.3 % for the second 
fraction. Table 1 shows that 6 out of 21 plans (28.6%) 
exceeded the standard department practice for bladder for 
both fractions and only 4 plans (19%) exceeded the standard 
department practice for rectum dose for both fractions. 
Generally, the dose to the OAR for either bladder or rectum 
of fraction 1 was higher compared with fraction 2. As 
applicator is a rigid device, it was a challenge in order to 
repack to adjust the insertion after the patients went out from 
the operation theater as all procedures were performed under 
conscious sedation. Then for the next fraction of treatment, 
the oncologist was aware and made some adjustment for 
the insertion procedure to reduce dose to OAR. 
 There are several factors that affected doses to OAR in 
brachytherapy treatment. Dose to the rectum and bladder 
depends upon the patient’s anatomy, disease extent, 
applicator design, technical details of the insertion and 
FIGURE 1. Fletcher-Williamson applicator set  FIGURE 2. Ring applicator set  
FIGURE 3. Reconstructions of applicators and identification 
of OARs points and point A
 FIGURE 4. Dose distribution calculated by Oncentra 
brachytherapy treatment planning software
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accuracy in reconstruction procedures. Since there are 
anatomy variations between each patient, it will affect 
the dose of bladder and rectum (Hunter et al. 2001). This 
is because to the distance between cervix to rectum or 
cervix to bladder depends on the individual’s anatomy 
and it is different for each patient. The distance between 
the posterior bladder wall and the active sources is 
also an important factor affecting the bladder dose in 
brachytherapy, which is different for each individual 
patient. Bladder distention may change this distance due 
to the increase of bladder volume. The bladder distention 
is also different in each individual patient, whether the 
patients are advised to empty the bladder before insertion 
procedures are carried out to minimize the bladder volume.
Besides, an applicator is also one of the contributors to the 
variation in doses to OARs. An applicator is a rigid device 
and made of stainless steel. It is inserted into the patients’ 
vaginal and uterine cavities, with sufficient packing around 
the applicator. The applicator set consists of combination 
of a pair of ovoid and a tandem. The size of ovoid and the 
length of tandem applied for ICBT are the major factors 
that affect the dose to the organ at risks. The size of 
FIGURE 5. Percentage of bladder dose to point A for each patient of ICBT; (  ): Fraction 1  
and (  ): Fraction 2; patient 1-17 used Fletcher-Williamson, patient 18-19 used ring and 
patient 20-21 used Fletcher-Williamson (fraction 1) and ring applicators (fraction 2)
 
FIGURE 6. Percentage of rectum dose to point A for each patient of ICBT; (  ): Fraction 1 and (  ): 
Fraction 2): Fraction 2; patient 1-17 used Fletcher-Williamson, patient 18-19 used ring and patient 20-21 
used Fletcher-Williamson (fraction 1) and ring applicators (fraction 2)
 
TABLE 1. Number of patients with the total OARs exceeding 
standard department practice
Bladder Rectum
Number of patients (n = 21) 6/21 4/21
Percentage (%) 28.6 19.0
*Bladder doses < 80% of dose for point A * Rectum doses < 60% of dose for point A 
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ovoid represents the diameter of the ovoid and the dose 
is more uniform as the diameter of the ovoid increases. 
More scattered photons that attenuated within the ovoid 
materials lost its energy to reach point A (prescription 
point). Thus, only primary photons are distributed to the 
prescription point and at the same time less dose to the 
bladder and rectum. Most of the patients treated in this 
study have ovoid’s size of 1.5 cm diameter (13 out of 
21) and the number of patients surpassed 80 and 60% of 
the prescribed dose at point A for bladder and rectum, 
respectively, were 6 out of 21 for bladder and only 1 out 
of 21 for rectum. It shows that ovoid with smaller size is 
unable to filter scattered photon and gives higher dose to 
OARs. The lengths of tandem varied among the patients. 
The shortest was 3 cm while the longest length 6 cm. This 
was decided by the doctor based on the disease or stage 
of cancer. Most of the patients in this study were treated 
with tandem length ≤5 cm (14 out of 21) and the number 
of patients surpassed 80 and 60% of the prescribed dose 
at point A for bladder and rectum, respectively, were 5 out 
of 21 for bladder and 3 out of 21 for rectum. This shows 
that shorter tandems have a tendency to increase the doses 
of rectum and bladder.
 Other than that, the technical details during the 
insertion of the applicator affect the variation of doses 
to OARs. The insertion of an applicator depends on the 
doctor’s skills and experiences in handling the procedures. 
Inadequate packing may cause higher dose to OAR and 
it challenges the oncologist to place the applicator with 
adequate packing for each insertion and each individual 
patient. As all procedures were performed under conscious 
sedation, sufficient packing was difficult, as well as the 
patient’s movement during the procedures. A gauze pack 
serves two purposes; it pushes the rectum and bladder away 
from the applicator and produces enough immobilization to 
the applicator in situ. Gauze packing is one of the factors 
affecting the dose to rectum and bladder (Garipagaoglu 
et al. 2006). Patient’s movements also greatly affect 
the variation doses to bladder and rectum. Not only the 
movements happened during the insertion procedures in the 
operation theater, but it could also happen while the patient 
was transferred to the couch for simulation procedures. 
Patient’s movements in any intracavitary brachytherapy 
procedure can displace the applicators, especially the 
tandem. Anterior shifts are correlated with high bladder 
dose differences. Immobilization of the patient’s hips and 
legs, as well as stabilization of applicators, would reduce 
these shifts (Pham et al. 1998). 
 The variations in OAR doses may also be the 
consequence of some factors such as the technique used 
to define prescription points (point A), the accuracy of 
rectum and bladder points’ position, the image quality 
of orthogonal radiographs and accuracy of applicator 
reconstruction in 2D planning. It is difficult to mark the 
rectum and bladder points in AP radiograph and identify the 
rectum points because the image of rectum marker could be 
superimposed with bladder marker and dummies inside the 
applicators. The rectum position can be easily identified in 
lateral radiograph. In contrast, the bladder points are easily 
identified in AP radiograph and in some cases, it is difficult 
in lateral radiograph because the bladder image was cut 
off by field size collimation. In order to improve image 
quality, collimation of filed size area must be sufficient. 
Then, it improved the orthogonal radiograph contrast for 
better visualization of smaller object images especially 
the dummies inside the applicators. The accuracy of 
reconstruction in 2D planning depends highly on the 
image of dummies identified in orthogonal radiographs. 
This is because the reconstructions of applicators based on 
the identification of dummies and the accuracy could be 
analyzed with reconstruction shift between AP and lateral 
radiographs. It would be difficult to identify the dummies 
in AP radiographs when its images were superimposed with 
images of bladder and rectum markers. In some cases, it 
was impossible to obtain clarity due to overlap of ovoid 
in lateral radiograph. The dummies inside the applicator 
were difficult to identify in lateral radiograph because of 
the thickness of pelvis’s tissues.
FIGURE 7. Mean percentages of bladder and rectum doses to point A for each patient 
of ICBT; (  ): Bladder and (  ): Rectum
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 Figure 7 shows the mean percentages of bladder and 
rectum doses to point A for each patient of ICBT. The mean 
percentages of rectum and bladder doses of ICBT for 21 
selected patients were 47.27 and 75.59%, respectively. 
Figure 8 shows the total dose to bladder and rectum, 
respectively, received by each individual patient from the 
external beam radiotherapy and brachytherapy treatments. 
For EBRT, all these 21 patients had received the dose of 45 
Gy. The irradiation field included the pelvic area, therefore 
45 Gy of dose also tended to receive by bladder and rectum. 
The results showed that the dose to bladder was still below 
the tolerance dose which is 60 Gy for each patient after 
receiving external beam radiotherapy and brachytherapy 
treatments. Besides, the dose tolerance for rectum should 
be less than 50 Gy and only 4 patients received the dose 
over the tolerance dose. The mean rectum and bladder total 
doses received by 21 selected patients from ICBT and EBRT 
were 49.26 and 51.8 Gy, respectively.
CONCLUSION
In this retrospective study, the results showed that the 
mean percentages of rectum and bladder doses of ICBT for 
21 selected patients were 47.27 and 75.59%, respectively. 
We had observed that the doses to OAR differed between 
different applicator sets applied for ICBT. The dose to 
bladder and rectum were also various compared to the 
first fraction and the second fraction of treatment. The 
combinations of ovoid’s size, the length of tandem and the 
anatomy variations between each patient were contributing 
factors that affects the dose to the OAR. In this study, the 
doses to OARs were below the tolerance dose of each OAR 
after receiving HDR intracavitary brachytherapy treatment. 
Thus, it is important to keep the dose to these organs as 
low as possible with guidance from reference document 
to avoid the late complication due to radiation side-effect. 
Therefore, the ICRU reference points can still be used the 
2D brachytherapy treatment planning in evaluating the 
OAR doses.
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